GlassScriptPhysician profile
Wenwu Jin
NPI 1003051780
$11,902.30
in general payments reported to CMS, 2019-2025
33 companies · $6,743 in 2025
The $6,743 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $407 · 2021: $536 · 2022: $1,012 · 2023: $754 · 2024: $714 · 2025: $6,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $2,796 · Travel and Lodging: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.11 |
| Education | $2,795.95 |
| Travel and Lodging | $2,335.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,753.10 | 2025 | |
| Janssen Biotech, INC. | $1,561.01 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $1,441.44 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $746.75 | 2022-2025 | |
| Pfizer INC. | $356.51 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.90 | 2019-2023 | |
| Dentsply Ih INC. | $323.09 | 2019 | |
| Sumitomo Pharma America, INC. | $269.45 | 2023-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $236.86 | 2019-2025 | Adstiladrin |
| Gilead Sciences, INC. | $230.95 | 2019-2023 | Vemlidy |
| Boston Scientific Corporation | $203.07 | 2019-2023 | Rezum Generator |
| Dendreon Pharmaceuticals LLC | $178.18 | 2019-2025 | Provenge |
| Janssen Pharmaceuticals, INC | $138.97 | 2021-2024 | Xarelto |
| Amgen INC. | $99.06 | 2022 | |
| Endo Pharmaceuticals INC. | $92.66 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $88.43 | 2022-2025 | |
| Urovant Sciences INC | $86.98 | 2022 | |
| Urogen Pharma, INC. | $78.52 | 2022-2023 | Jelmyto |
| Abbvie INC. | $71.32 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $65.17 | 2025 | Lynparza |
| Verity Pharmaceuticals INC. | $56.62 | 2025 | Trelstar |
| Abc Home Medical Supply, INC. | $56.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $54.81 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $53.33 | 2022-2025 | Welireg, Keytruda |
| Neotract INC. | $50.13 | 2019 | |
| Angiodynamics, INC. | $46.85 | 2025 | Nanoknife |
| Tolmar Pharmaceuticals, INC. | $44.95 | 2019 | |
| Allergan, INC. | $41.87 | 2019-2022 | |
| Myovant Sciences INC. | $36.87 | 2021 | |
| Immunitybio, INC. | $34.56 | 2025 | |
| Photocure INC | $29.96 | 2022 | |
| Olympus America INC. | $29.43 | 2024 | Itind System |
| Dornier Medtech America, INC | $19.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenwu Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.